RxDoctor Payments Data

Khurram Nazir, MD

Neurology · Panama City, FLNPI 1619261252

Payments from drug & device makers

$192,969in general payments, 2019–2025

Across 1,093 payments — averaging $176.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$102K
  • Teva Pharmaceuticals USA, Inc.$30K
  • Impel Pharmaceuticals Inc.$22K
  • Biohaven Pharmaceuticals, Inc.$20K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Novartis$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$19,48810%
  • Speaking & faculty fees$140,01973%
  • Travel & lodging$13,2517%
  • Food & beverage$20,18610%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)192$102,313
Teva Pharmaceuticals USA, Inc.44$30,484
Impel Pharmaceuticals Inc.21$22,141
Biohaven Pharmaceuticals, Inc.41$20,100
Biohaven Pharmaceutical Holding Company Ltd.26$2,856
Novartis92$1,375
Lilly USA, LLC46$939
Amgen(2 entities)51$915
Pfizer68$890
UCB, Inc.35$788
AstraZeneca29$700
Jazz Pharmaceuticals Inc.33$696
Argenx US, Inc.14$590
Biogen34$560
Lundbeck LLC32$549
Acadia Pharmaceuticals Inc26$512
SK Life Science, Inc.21$459
MDD US Operations, LLC15$386
Sanofi16$309
CSL Behring13$299
Sunovion Pharmaceuticals Inc.17$283
EMD Serono, Inc.15$275
Bristol Myers Squibb15$266
Eisai Inc.8$260
Genentech USA, Inc.11$237
Harmony Biosciences LLC11$230
Abbott6$212
Otsuka America Pharmaceutical, Inc.5$195
Octapharma USA, Inc.9$190
Nevro Corp.6$189
Takeda Pharmaceuticals U.S.A., Inc.8$188
Grifols USA, LLC8$177
Axsome Therapeutics, Inc.3$147
Supernus Pharmaceuticals, Inc.14$144
Tanabe Pharma America, Inc.6$123
E.r. Squibb & Sons, L.L.C.1$115
Boston Scientific6$113
Adamas Pharmaceuticals, Inc.5$112
Catalyst Pharmaceuticals, Inc.5$106
Merz Pharmaceuticals, LLC4$100
TG Therapeutics, Inc.5$100
Upsher-smith Laboratories LLC6$98
Livanova USA, Inc.5$92
ANI Pharmaceuticals, Inc.3$91
GE HealthCare4$91
Amneal Pharmaceuticals LLC6$91
Avanir Pharmaceuticals, Inc.5$84
Acorda Therapeutics, Inc4$79
Merck5$79
Johnson & Johnson(2 entities)3$53
Greenwich Biosciences, Inc.3$52
Scilex Pharmaceuticals Inc.3$51
Biodelivery Sciences International, Inc.4$50
Medtronic3$50
Alnylam Pharmaceuticals Inc.2$44
Kyowa Kirin, Inc.3$39
C2n Diagnostics, LLC2$38
Avadel CNS Pharmaceuticals, LLC1$32
Collegium Pharmaceutical, Inc.2$29
Merz North America, Inc.2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,969 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$441,798
Medicare patients
1,278
Services billed
3,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5027$534,829
RystiggoRozanolixizumab-Noli12$379,946
XywavSodium,calcium,mag,pot Oxybate12$239,419
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5037$210,161
BotoxOnabotulinumtoxina61$81,127
RytaryCarbidopa/Levodopa20$30,782
Nurtec OdtRimegepant Sulfate19$27,976
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen937$24,097
OxycontinOxycodone Hcl21$17,735
Aimovig AutoinjectorErenumab-Aooe24$17,587
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen486$17,122
Emgality PenGalcanezumab-Gnlm22$15,599
XeominIncobotulinumtoxina17$15,547
NucyntaTapentadol Hcl12$11,928
Xtampza ErOxycodone Myristate23$11,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Rystiggo$788$379,94612 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$188$210,16137 claims
AbbVieBotox$102,313$81,12761 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$91$32,33651 claims
PfizerNurtec Odt$890$27,97619 claims
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$29$23,79835 claims
Merz North America, Inc.Xeomin$25$15,54717 claims
MerckBelsomra$79$9,48018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →